Spectrum of statin hepatotoxicity: Experience of the drug‐induced liver injury network
Mark W. Russo, Jay H. Hoofnagle, Jiezhun Gu, Robert J. Fontana, Huiman Barnhart, David E. Kleiner, Naga Chalasani, Herbert L. Bonkovsky – 2 April 2014 – The HMG‐CoA reductase inhibitors (statins) are widely prescribed for patients with hyperlipidemia and are generally well tolerated. Mild elevations in serum aminotransferases arise in up to 3% of treated patients, but clinically apparent drug‐induced liver injury is rare. The aim of this study is to report the presenting features and outcomes of 22 patients with clinically apparent liver injury due to statins.